董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Anatoly Dritschilo | 男 | Chairman of the board and Chief Executive Officer | 80 | 33.42万美元 | 未持股 | 2026-01-08 |
| Oleh Nabyt | 男 | Director | 32 | 22.08万美元 | 未持股 | 2026-01-08 |
| George Scorsis | -- | Director | -- | 22.68万美元 | 0.37 | 2026-01-08 |
| Adam Chambers | -- | Director | -- | 0.78万美元 | 未持股 | 2026-01-08 |
| Angel Liriano | -- | Director | -- | 0.76万美元 | 未持股 | 2026-01-08 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Anatoly Dritschilo | 男 | Chairman of the board and Chief Executive Officer | 80 | 33.42万美元 | 未持股 | 2026-01-08 |
| Mira Jung | 女 | Chief Scientific Officer | 76 | 未披露 | 未持股 | 2026-01-08 |
| Tyvin Rich | 男 | Chief Clinical Officer | 77 | 21.80万美元 | 未持股 | 2026-01-08 |
| Christopher R. Cooper | -- | Interim Chief Executive Officer | -- | 19.35万美元 | 未持股 | 2026-01-08 |
| Yuying Liang | 女 | Chief Financial Officer | 35 | 未披露 | 未持股 | 2026-01-08 |
| Yuying Liang | 女 | Chief Financial Officer | 35 | 未披露 | 未持股 | 2026-01-08 |
董事简历
中英对照 | 中文 | 英文- Anatoly Dritschilo
-
Anatoly Dritschilo，担任公司的联席创始人，也曾担任董事会主席兼首席执行官（2012年12月公司创立以来）。他是通过培训的放射肿瘤学家，也担任多个卫生保健领导岗位。他曾担任Georgetown University Medical School（位于华盛顿特区）的系主任（1980年至2016年）、MedStar-Georgetown University Hospital的放射肿瘤科主任（2005年至2016年）、Georgetown University Hospital的医疗主管（1994年至1997年）、the NCI-funded Lombardi Comprehensive Cancer Center的临时主管（2005年至2007年）。他也曾任职于MedStar-Georgetown University Hospital、the National Capital Rehabilitation Hospital、the MedStar Research Institute的董事会。他拥有200多份科学出版物和12项发布专利，因此成为the National Academy of Inventors的成员。他持有the University of Pennsylvania的化学工程学士学位、the College of Medicine of New Jersey的医学学位，并获得the Harvard, Joint Center for Radiation Therapy的住院医师培训。他的资格支持他担任Shuttle Pharmaceuticals, Inc的首席执行官兼董事会主席。
Anatoly Dritschilo,is a co-founder of the Company and has served as Chief Executive Officer and Chairman of the Board of Directors since the Company's formation in December 2012. Dr. Dritschilo is a radiation oncologist by training and has held multiple leadership positions in health care. At Georgetown University Medical School in Washington, D.C., he served principally as Department Chair from 1980 to 2022; Chief of Radiation Oncology at MedStar-Georgetown University Hospital from 2005 to 2022; Medical Director of Georgetown University Hospital from 1994 to 1997; and Interim Director of the NCI-funded Lombardi Comprehensive Cancer Center from 2005 to 2007. He has also served on the boards of directors of MedStar-Georgetown University Hospital, the National Capital Rehabilitation Hospital, and the MedStar Health Research Institute. Previously, he was a founding director of Oncomed, Inc. and a member of the board of directors of Neopharm, Inc. His 250+ scientific publications and 12 issued patents have earned him election as a Fellow of the National Academy of Inventors. Dr. Dritschilo holds a Bachelor of Science degree in Chemical Engineering from the University of Pennsylvania, a medical degree from the College of Medicine of New Jersey and residency training from the Harvard Joint Center for Radiation Therapy. - Anatoly Dritschilo，担任公司的联席创始人，也曾担任董事会主席兼首席执行官（2012年12月公司创立以来）。他是通过培训的放射肿瘤学家，也担任多个卫生保健领导岗位。他曾担任Georgetown University Medical School（位于华盛顿特区）的系主任（1980年至2016年）、MedStar-Georgetown University Hospital的放射肿瘤科主任（2005年至2016年）、Georgetown University Hospital的医疗主管（1994年至1997年）、the NCI-funded Lombardi Comprehensive Cancer Center的临时主管（2005年至2007年）。他也曾任职于MedStar-Georgetown University Hospital、the National Capital Rehabilitation Hospital、the MedStar Research Institute的董事会。他拥有200多份科学出版物和12项发布专利，因此成为the National Academy of Inventors的成员。他持有the University of Pennsylvania的化学工程学士学位、the College of Medicine of New Jersey的医学学位，并获得the Harvard, Joint Center for Radiation Therapy的住院医师培训。他的资格支持他担任Shuttle Pharmaceuticals, Inc的首席执行官兼董事会主席。
- Anatoly Dritschilo,is a co-founder of the Company and has served as Chief Executive Officer and Chairman of the Board of Directors since the Company's formation in December 2012. Dr. Dritschilo is a radiation oncologist by training and has held multiple leadership positions in health care. At Georgetown University Medical School in Washington, D.C., he served principally as Department Chair from 1980 to 2022; Chief of Radiation Oncology at MedStar-Georgetown University Hospital from 2005 to 2022; Medical Director of Georgetown University Hospital from 1994 to 1997; and Interim Director of the NCI-funded Lombardi Comprehensive Cancer Center from 2005 to 2007. He has also served on the boards of directors of MedStar-Georgetown University Hospital, the National Capital Rehabilitation Hospital, and the MedStar Health Research Institute. Previously, he was a founding director of Oncomed, Inc. and a member of the board of directors of Neopharm, Inc. His 250+ scientific publications and 12 issued patents have earned him election as a Fellow of the National Academy of Inventors. Dr. Dritschilo holds a Bachelor of Science degree in Chemical Engineering from the University of Pennsylvania, a medical degree from the College of Medicine of New Jersey and residency training from the Harvard Joint Center for Radiation Therapy.
- Oleh Nabyt
-
Oleh Nabyt，自2025年2月起担任公司董事。Nabyt先生在跨多个行业的财务分析和流程改进方面有着良好的记录，在角色和职责方面取得了重大进展。2017年6月至2018年9月，Nabyt先生在硕腾担任金融分析师。在硕腾，他领导数据治理、开发KPI仪表板、提高运营可见性，并在关键增长阶段简化财务流程方面发挥了关键作用。2018年9月至2020年4月，Nabyt先生担任新上市公司Hudson Group FP & A团队的首席财务助理。在Hudson Group，他曾在首席财务官直属部门工作，并与投资者关系部密切合作。从2021年5月至今，Nabyt先生在NCLH担任财务经理，负责监督5亿美元的预算，继续承担日益复杂的财务管理和领导职责。Nabyt先生于2016年获得罗格斯大学学士学位。他丰富的经验使他成为一名战略财务专业人士，擅长推动卓越运营和财务效率。
Oleh Nabyt,has served as director of the Company since February 2025. Mr. Nabyt comes with a strong track record of financial analysis and process improvement across multiple industries, with significant progression in roles and responsibilities. From June 2017 to September 2018, Mr. Nabyt served as Financial Analyst at Zoetis. At Zoetis, he led data governance, developed KPI dashboards, enhanced operational visibility, and played a key role in streamlining financial processes during a critical growth phase. From September 2018 to April 2020, Mr. Nabyt served as a lead Financial Associate on the FP&A team at Hudson Group, a newly public company. At Hudson Group, he worked directly under the Chief Financial Officer and closely with Investor Relations. From May 2021 to present, Mr. Nabyt has served as Finance Manager at NCLH, where he oversees a $500M budget, continuing to take on increasingly complex financial management and leadership responsibilities. Mr. Nabyt received his bachelor's degree from Rutgers University in 2016. His diverse experience positions him as a strategic finance professional, adept at driving both operational excellence and financial efficiency. - Oleh Nabyt，自2025年2月起担任公司董事。Nabyt先生在跨多个行业的财务分析和流程改进方面有着良好的记录，在角色和职责方面取得了重大进展。2017年6月至2018年9月，Nabyt先生在硕腾担任金融分析师。在硕腾，他领导数据治理、开发KPI仪表板、提高运营可见性，并在关键增长阶段简化财务流程方面发挥了关键作用。2018年9月至2020年4月，Nabyt先生担任新上市公司Hudson Group FP & A团队的首席财务助理。在Hudson Group，他曾在首席财务官直属部门工作，并与投资者关系部密切合作。从2021年5月至今，Nabyt先生在NCLH担任财务经理，负责监督5亿美元的预算，继续承担日益复杂的财务管理和领导职责。Nabyt先生于2016年获得罗格斯大学学士学位。他丰富的经验使他成为一名战略财务专业人士，擅长推动卓越运营和财务效率。
- Oleh Nabyt,has served as director of the Company since February 2025. Mr. Nabyt comes with a strong track record of financial analysis and process improvement across multiple industries, with significant progression in roles and responsibilities. From June 2017 to September 2018, Mr. Nabyt served as Financial Analyst at Zoetis. At Zoetis, he led data governance, developed KPI dashboards, enhanced operational visibility, and played a key role in streamlining financial processes during a critical growth phase. From September 2018 to April 2020, Mr. Nabyt served as a lead Financial Associate on the FP&A team at Hudson Group, a newly public company. At Hudson Group, he worked directly under the Chief Financial Officer and closely with Investor Relations. From May 2021 to present, Mr. Nabyt has served as Finance Manager at NCLH, where he oversees a $500M budget, continuing to take on increasingly complex financial management and leadership responsibilities. Mr. Nabyt received his bachelor's degree from Rutgers University in 2016. His diverse experience positions him as a strategic finance professional, adept at driving both operational excellence and financial efficiency.
- George Scorsis
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Adam Chambers
-
Adam Chambers是Bowery Consulting Group Inc.的负责人，该公司是2025年2月28日公司循环贷款协议下的贷款人。
Adam Chambers,is the principal of Bowery Consulting Group Inc., which is the lender under the Company's revolving loan agreement, dated February 28, 2025. - Adam Chambers是Bowery Consulting Group Inc.的负责人，该公司是2025年2月28日公司循环贷款协议下的贷款人。
- Adam Chambers,is the principal of Bowery Consulting Group Inc., which is the lender under the Company's revolving loan agreement, dated February 28, 2025.
- Angel Liriano
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
高管简历
中英对照 | 中文 | 英文- Anatoly Dritschilo
Anatoly Dritschilo，担任公司的联席创始人，也曾担任董事会主席兼首席执行官（2012年12月公司创立以来）。他是通过培训的放射肿瘤学家，也担任多个卫生保健领导岗位。他曾担任Georgetown University Medical School（位于华盛顿特区）的系主任（1980年至2016年）、MedStar-Georgetown University Hospital的放射肿瘤科主任（2005年至2016年）、Georgetown University Hospital的医疗主管（1994年至1997年）、the NCI-funded Lombardi Comprehensive Cancer Center的临时主管（2005年至2007年）。他也曾任职于MedStar-Georgetown University Hospital、the National Capital Rehabilitation Hospital、the MedStar Research Institute的董事会。他拥有200多份科学出版物和12项发布专利，因此成为the National Academy of Inventors的成员。他持有the University of Pennsylvania的化学工程学士学位、the College of Medicine of New Jersey的医学学位，并获得the Harvard, Joint Center for Radiation Therapy的住院医师培训。他的资格支持他担任Shuttle Pharmaceuticals, Inc的首席执行官兼董事会主席。
Anatoly Dritschilo,is a co-founder of the Company and has served as Chief Executive Officer and Chairman of the Board of Directors since the Company's formation in December 2012. Dr. Dritschilo is a radiation oncologist by training and has held multiple leadership positions in health care. At Georgetown University Medical School in Washington, D.C., he served principally as Department Chair from 1980 to 2022; Chief of Radiation Oncology at MedStar-Georgetown University Hospital from 2005 to 2022; Medical Director of Georgetown University Hospital from 1994 to 1997; and Interim Director of the NCI-funded Lombardi Comprehensive Cancer Center from 2005 to 2007. He has also served on the boards of directors of MedStar-Georgetown University Hospital, the National Capital Rehabilitation Hospital, and the MedStar Health Research Institute. Previously, he was a founding director of Oncomed, Inc. and a member of the board of directors of Neopharm, Inc. His 250+ scientific publications and 12 issued patents have earned him election as a Fellow of the National Academy of Inventors. Dr. Dritschilo holds a Bachelor of Science degree in Chemical Engineering from the University of Pennsylvania, a medical degree from the College of Medicine of New Jersey and residency training from the Harvard Joint Center for Radiation Therapy.- Anatoly Dritschilo，担任公司的联席创始人，也曾担任董事会主席兼首席执行官（2012年12月公司创立以来）。他是通过培训的放射肿瘤学家，也担任多个卫生保健领导岗位。他曾担任Georgetown University Medical School（位于华盛顿特区）的系主任（1980年至2016年）、MedStar-Georgetown University Hospital的放射肿瘤科主任（2005年至2016年）、Georgetown University Hospital的医疗主管（1994年至1997年）、the NCI-funded Lombardi Comprehensive Cancer Center的临时主管（2005年至2007年）。他也曾任职于MedStar-Georgetown University Hospital、the National Capital Rehabilitation Hospital、the MedStar Research Institute的董事会。他拥有200多份科学出版物和12项发布专利，因此成为the National Academy of Inventors的成员。他持有the University of Pennsylvania的化学工程学士学位、the College of Medicine of New Jersey的医学学位，并获得the Harvard, Joint Center for Radiation Therapy的住院医师培训。他的资格支持他担任Shuttle Pharmaceuticals, Inc的首席执行官兼董事会主席。
- Anatoly Dritschilo,is a co-founder of the Company and has served as Chief Executive Officer and Chairman of the Board of Directors since the Company's formation in December 2012. Dr. Dritschilo is a radiation oncologist by training and has held multiple leadership positions in health care. At Georgetown University Medical School in Washington, D.C., he served principally as Department Chair from 1980 to 2022; Chief of Radiation Oncology at MedStar-Georgetown University Hospital from 2005 to 2022; Medical Director of Georgetown University Hospital from 1994 to 1997; and Interim Director of the NCI-funded Lombardi Comprehensive Cancer Center from 2005 to 2007. He has also served on the boards of directors of MedStar-Georgetown University Hospital, the National Capital Rehabilitation Hospital, and the MedStar Health Research Institute. Previously, he was a founding director of Oncomed, Inc. and a member of the board of directors of Neopharm, Inc. His 250+ scientific publications and 12 issued patents have earned him election as a Fellow of the National Academy of Inventors. Dr. Dritschilo holds a Bachelor of Science degree in Chemical Engineering from the University of Pennsylvania, a medical degree from the College of Medicine of New Jersey and residency training from the Harvard Joint Center for Radiation Therapy.
- Mira Jung
Mira Jung 是 Shuttle Pharmaceuticals Holdings, Inc. 公司的联合创始人，目前担任 Shuttle Pharmaceuticals Holdings, Inc. 生物学首席科学官，并且是 Shuttle Pharmaceuticals Holdings, Inc. 董事会成员 Shuttle Pharmaceuticals Holdings, Inc. 。 成立于2012年12月至2019年。 自2005年起，Jung 博士一直担任乔治城大学医学院放射医学和微生物学教授，在分子放射生物学研究方面拥有20多年的经验。她是辐射抗性机制和 HDAC 抑制剂在改变辐射反应中的作用方面的专家。 Jung 博士的研究得到了 NIH 和 DOD 的资助，发表了 100 篇出版物和 6 项已授权专利，其中包括首次报道的 HDAC 抑制剂类药物可以改变癌细胞的抗辐射性和保护正常组织免受辐射损伤。 Jung 博士拥有堪萨斯大学微生物学和分子病毒学硕士学位和博士学位。
Mira Jung,a co-founder of Shuttle Pharmaceuticals Holdings, Inc. company, has served as Shuttle Pharmaceuticals Holdings, Inc. Chief Scientific Officer for Biology since December 2012, and was a member of Shuttle Pharmaceuticals Holdings, Inc. board of directors from Shuttle Pharmaceuticals Holdings, Inc. formation in December 2012 until 2019. Since 2004, Dr. Jung has served as Professor of Radiation Medicine and Microbiology at Georgetown University Medical School. With over 30 years of experience in molecular radiation biology research, she is an expert in mechanisms of radiation resistance and on the roles of HDAC inhibitors in modifying the radiation response. Dr. Jung's research has been funded by NIH and the DOD leading to 100+ publications and nine patents granted by the USPTO, including the first reports of HDAC inhibitor drug classes modifying cancer cell radiation resistance and protecting normal tissues from radiation damage. Dr. Jung holds an MA degree and a PhD in Microbiology and Molecular Virology from the University of Kansas, Lawrence.- Mira Jung 是 Shuttle Pharmaceuticals Holdings, Inc. 公司的联合创始人，目前担任 Shuttle Pharmaceuticals Holdings, Inc. 生物学首席科学官，并且是 Shuttle Pharmaceuticals Holdings, Inc. 董事会成员 Shuttle Pharmaceuticals Holdings, Inc. 。 成立于2012年12月至2019年。 自2005年起，Jung 博士一直担任乔治城大学医学院放射医学和微生物学教授，在分子放射生物学研究方面拥有20多年的经验。她是辐射抗性机制和 HDAC 抑制剂在改变辐射反应中的作用方面的专家。 Jung 博士的研究得到了 NIH 和 DOD 的资助，发表了 100 篇出版物和 6 项已授权专利，其中包括首次报道的 HDAC 抑制剂类药物可以改变癌细胞的抗辐射性和保护正常组织免受辐射损伤。 Jung 博士拥有堪萨斯大学微生物学和分子病毒学硕士学位和博士学位。
- Mira Jung,a co-founder of Shuttle Pharmaceuticals Holdings, Inc. company, has served as Shuttle Pharmaceuticals Holdings, Inc. Chief Scientific Officer for Biology since December 2012, and was a member of Shuttle Pharmaceuticals Holdings, Inc. board of directors from Shuttle Pharmaceuticals Holdings, Inc. formation in December 2012 until 2019. Since 2004, Dr. Jung has served as Professor of Radiation Medicine and Microbiology at Georgetown University Medical School. With over 30 years of experience in molecular radiation biology research, she is an expert in mechanisms of radiation resistance and on the roles of HDAC inhibitors in modifying the radiation response. Dr. Jung's research has been funded by NIH and the DOD leading to 100+ publications and nine patents granted by the USPTO, including the first reports of HDAC inhibitor drug classes modifying cancer cell radiation resistance and protecting normal tissues from radiation damage. Dr. Jung holds an MA degree and a PhD in Microbiology and Molecular Virology from the University of Kansas, Lawrence.
- Tyvin Rich
Tyvin Rich担任Shuttle Pharmaceuticals控股公司的首席医疗官，负责新型辐射增敏剂的临床开发。自2010年以来，Rich博士一直担任弗吉尼亚州汉普顿汉普顿大学质子治疗研究所的放射肿瘤学家和弗吉尼亚大学放射肿瘤学系Health Sciences中心的名誉教授。从1995年到2010年，Rich博士是弗吉尼亚大学Health Sciences中心治疗放射学和肿瘤学系的教授和主席。在此之前，从1984年到1995年，Rich博士是德克萨斯大学安德森癌症中心放射治疗系的放射治疗教授和诊所主任。他曾担任RTOG临床试验的协议主席，该试验促进了放化疗用于治疗直肠癌和胰腺癌。他是输注5-氟尿嘧啶用于胃肠癌放化疗的专家，撰写了200多篇科学文章、评论和书籍章节。Rich博士在罗格斯大学获得本科学位，在弗吉尼亚大学获得医学学位，并在乔治城大学医学中心完成内科住院治疗，并在哈佛医学院马萨诸塞州总医院完成放射治疗。
Tyvin Rich,serves as Shuttle Pharmaceuticals Holdings, Inc. company's Chief Medical Officer and is responsible for the clinical development of novel radiation sensitizers. Since 2010, Dr. Rich has served as a Staff Radiation Oncologist at the Hampton University Proton Therapy Institute in Hampton Virginia and Professor Emeritus at University of Virginia Health Sciences Center, Department of Radiation Oncology. From 1995 until 2010, Dr. Rich was a Professor and Chairman of the Department of Therapeutic Radiology and Oncology at the University of Virginia Health Sciences Center. Prior to that, from 1984 through 1995, Dr. Rich was a Professor of Radiotherapy and Director of Clinics in the Department of Radiotherapy of the University of Texas M. D. Anderson Cancer Center. He has served as the protocol chair for RTOG clinical trials that advanced the Shuttle Pharmaceuticals Holdings, Inc. e of chemoradiation for the treatment of rectal and pancreatic cancers. He is an expert in the applications of infusional 5-Fluorouracil for chemoradiation therapy of gastro-intestinal cancers and has authored more than 200 scientific articles, reviews and book chapters. Dr. Rich received his undergraduate degree at Rutgers University, his medical degree at the University of Virginia, and completed residencies in internal medicine at Georgetown University Medical Center and radiation therapy at Massachusetts General Hospital, Harvard Medical School.- Tyvin Rich担任Shuttle Pharmaceuticals控股公司的首席医疗官，负责新型辐射增敏剂的临床开发。自2010年以来，Rich博士一直担任弗吉尼亚州汉普顿汉普顿大学质子治疗研究所的放射肿瘤学家和弗吉尼亚大学放射肿瘤学系Health Sciences中心的名誉教授。从1995年到2010年，Rich博士是弗吉尼亚大学Health Sciences中心治疗放射学和肿瘤学系的教授和主席。在此之前，从1984年到1995年，Rich博士是德克萨斯大学安德森癌症中心放射治疗系的放射治疗教授和诊所主任。他曾担任RTOG临床试验的协议主席，该试验促进了放化疗用于治疗直肠癌和胰腺癌。他是输注5-氟尿嘧啶用于胃肠癌放化疗的专家，撰写了200多篇科学文章、评论和书籍章节。Rich博士在罗格斯大学获得本科学位，在弗吉尼亚大学获得医学学位，并在乔治城大学医学中心完成内科住院治疗，并在哈佛医学院马萨诸塞州总医院完成放射治疗。
- Tyvin Rich,serves as Shuttle Pharmaceuticals Holdings, Inc. company's Chief Medical Officer and is responsible for the clinical development of novel radiation sensitizers. Since 2010, Dr. Rich has served as a Staff Radiation Oncologist at the Hampton University Proton Therapy Institute in Hampton Virginia and Professor Emeritus at University of Virginia Health Sciences Center, Department of Radiation Oncology. From 1995 until 2010, Dr. Rich was a Professor and Chairman of the Department of Therapeutic Radiology and Oncology at the University of Virginia Health Sciences Center. Prior to that, from 1984 through 1995, Dr. Rich was a Professor of Radiotherapy and Director of Clinics in the Department of Radiotherapy of the University of Texas M. D. Anderson Cancer Center. He has served as the protocol chair for RTOG clinical trials that advanced the Shuttle Pharmaceuticals Holdings, Inc. e of chemoradiation for the treatment of rectal and pancreatic cancers. He is an expert in the applications of infusional 5-Fluorouracil for chemoradiation therapy of gastro-intestinal cancers and has authored more than 200 scientific articles, reviews and book chapters. Dr. Rich received his undergraduate degree at Rutgers University, his medical degree at the University of Virginia, and completed residencies in internal medicine at Georgetown University Medical Center and radiation therapy at Massachusetts General Hospital, Harvard Medical School.
- Christopher R. Cooper
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Yuying Liang
YUYing Liang，是Canmore Financial Services Inc.和YUYing Liang Professional Corp.的负责人和董事，在企业会计、财务报告和CFO服务方面拥有丰富的经验。梁女士曾与多个行业的公共和私营公司广泛合作，提供财务领导和战略指导。梁女士拥有Simon Fraser大学工商管理学士学位，并拥有特许专业会计师（CPA）的专业称号。梁女士是Modern Plant Based Foods Inc.、Montego Resources Inc.和Ultra Brands Ltd.的首席财务官兼董事；BlockchainK2 Corp、Goldhills Holding Ltd.、Intact Gold Corp.、Kincora Copper Limited和Transatlantic Mining Corp.的首席财务官。
Yuying Liang has been serving as Ispecimen Inc.'s Chief Financial Officer since December 2024. Ms. Liang is the Principal and Director of Canmore Financial Services Inc. and Yuying Liang Professional Corp. with significant experience in corporate accounting, financial reporting, and CFO services. Ms. Liang has worked extensively with public and private companies across multiple sectors, providing financial leadership and strategic guidance. Ms. Liang holds a Bachelor of Business Administration from Simon Fraser University and holds the professional designation of chartered professional accountant (CPA). Ms. Liang is CFO and Director of Modern Plant Based Foods Inc., Montego Resources Inc. and Ultra Brands Ltd.; the CFO of BlockchainK2 Corp, Goldhills Holding Ltd., Intact Gold Corp., Kincora Copper Limited and Transatlantic Mining Corp.- YUYing Liang，是Canmore Financial Services Inc.和YUYing Liang Professional Corp.的负责人和董事，在企业会计、财务报告和CFO服务方面拥有丰富的经验。梁女士曾与多个行业的公共和私营公司广泛合作，提供财务领导和战略指导。梁女士拥有Simon Fraser大学工商管理学士学位，并拥有特许专业会计师（CPA）的专业称号。梁女士是Modern Plant Based Foods Inc.、Montego Resources Inc.和Ultra Brands Ltd.的首席财务官兼董事；BlockchainK2 Corp、Goldhills Holding Ltd.、Intact Gold Corp.、Kincora Copper Limited和Transatlantic Mining Corp.的首席财务官。
- Yuying Liang has been serving as Ispecimen Inc.'s Chief Financial Officer since December 2024. Ms. Liang is the Principal and Director of Canmore Financial Services Inc. and Yuying Liang Professional Corp. with significant experience in corporate accounting, financial reporting, and CFO services. Ms. Liang has worked extensively with public and private companies across multiple sectors, providing financial leadership and strategic guidance. Ms. Liang holds a Bachelor of Business Administration from Simon Fraser University and holds the professional designation of chartered professional accountant (CPA). Ms. Liang is CFO and Director of Modern Plant Based Foods Inc., Montego Resources Inc. and Ultra Brands Ltd.; the CFO of BlockchainK2 Corp, Goldhills Holding Ltd., Intact Gold Corp., Kincora Copper Limited and Transatlantic Mining Corp.
- Yuying Liang
梁育英，是一名注册会计师，在企业会计、财务报告、首席财务官服务方面拥有丰富的经验。梁女士与多个行业的公共和私营公司广泛合作，提供财务领导和战略指导。最近，梁女士于2024年12月13日被任命为iSpecimen Inc.的首席财务官。除了最近被任命为iSpecimen Inc.的首席财务官外，梁女士目前还担任BlockchainK2 Corp.、Goldhills Holding Ltd、Intact Gold Corp.、Kincora Copper Limited、Transatlantic Mining Corp.和Ultra Brands Ltd.的首席财务官。她还担任首席财务官以及Modern Plant-Based Foods Inc.和Montego Resources Inc.的董事。在这些职位上，梁女士负责监督合并财务报告，确保遵守国际财务报告准则和美国公认会计原则，并为执行团队和董事会提供战略指导。
Yuying Liang,is a certified public accountant with significant experience in corporate accounting, financial reporting, and chief financial officer services. Ms. Liang has worked extensively with public and private companies across multiple sectors, providing financial leadership and strategic guidance. Most recently, Ms. Liang was appointed Chief Financial Officer of iSpecimen Inc. on December 13, 2024.In addition to her recent appointment as Chief Financial Officer of iSpecimen Inc., Ms. Liang currently serves as Chief Financial Officer of BlockchainK2 Corp., Goldhills Holding Ltd, Intact Gold Corp., Kincora Copper Limited, Transatlantic Mining Corp., and Ultra Brands Ltd. She also serves as both Chief Financial Officer and Director of Modern Plant Based Foods Inc. and Montego Resources Inc. In these roles, Ms. Liang has overseen consolidated financial reporting, ensured compliance with IFRS and US GAAP, and provided strategic guidance to executive teams and boards of directors.- 梁育英，是一名注册会计师，在企业会计、财务报告、首席财务官服务方面拥有丰富的经验。梁女士与多个行业的公共和私营公司广泛合作，提供财务领导和战略指导。最近，梁女士于2024年12月13日被任命为iSpecimen Inc.的首席财务官。除了最近被任命为iSpecimen Inc.的首席财务官外，梁女士目前还担任BlockchainK2 Corp.、Goldhills Holding Ltd、Intact Gold Corp.、Kincora Copper Limited、Transatlantic Mining Corp.和Ultra Brands Ltd.的首席财务官。她还担任首席财务官以及Modern Plant-Based Foods Inc.和Montego Resources Inc.的董事。在这些职位上，梁女士负责监督合并财务报告，确保遵守国际财务报告准则和美国公认会计原则，并为执行团队和董事会提供战略指导。
- Yuying Liang,is a certified public accountant with significant experience in corporate accounting, financial reporting, and chief financial officer services. Ms. Liang has worked extensively with public and private companies across multiple sectors, providing financial leadership and strategic guidance. Most recently, Ms. Liang was appointed Chief Financial Officer of iSpecimen Inc. on December 13, 2024.In addition to her recent appointment as Chief Financial Officer of iSpecimen Inc., Ms. Liang currently serves as Chief Financial Officer of BlockchainK2 Corp., Goldhills Holding Ltd, Intact Gold Corp., Kincora Copper Limited, Transatlantic Mining Corp., and Ultra Brands Ltd. She also serves as both Chief Financial Officer and Director of Modern Plant Based Foods Inc. and Montego Resources Inc. In these roles, Ms. Liang has overseen consolidated financial reporting, ensured compliance with IFRS and US GAAP, and provided strategic guidance to executive teams and boards of directors.